Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.62 |
| ▸ | MLYCD | O95822 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | MMP13 | P45452 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27627004 | 0.92 | MAPK14 (0.52) | HDAC6MLYCDCA2MMP13KMT2A | |
| SCHEMBL10722498 | 0.88 | HDAC6 (0.77) | HDAC6MLYCDCA2MMP13KMT2A | |
| SCHEMBL14797370 | 0.84 | NAMPT (0.53) | HDAC6MLYCDCA2KMT2AMEN1 | |
| SCHEMBL3039617 | 0.84 | SMYD3 (0.53) | HDAC6MLYCDCA2NAMPT | |
| SCHEMBL25123079 | 0.83 | SMN1; SMN2 (0.76) | HDAC6MLYCDCA2MMP13KMT2A | |
| SCHEMBL4522241 | 0.83 | SMN1; SMN2 (0.76) | HDAC6MLYCDCA2MMP13KMT2A | |
| SCHEMBL8395225 | 0.83 | SMN1; SMN2 (0.76) | HDAC6MLYCDCA2MMP13KMT2A | |
| SCHEMBL4627972 | 0.83 | HDAC6 (0.55) | HDAC6MLYCDCA2MMP13KMT2A | |
| SCHEMBL8389571 | 0.82 | HDAC6 (0.68) | HDAC6MLYCDCA2MMP13KMT2A | |
| SCHEMBL17483892 | 0.82 | HDAC6 (0.70) | HDAC6MLYCDCA2MMP13KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3193603-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS | Epizyme, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016040498-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS | Epizyme, Inc. (US) | 2016-03-17 | — | — | WO | disclosed |
| US-7667036-B2 | MAPKAP-K2 (mitogen-activated protein kinase-activated protein kinase 2) inhibitors; inflammatory, autoimmune disease, destructive bone disorder, cancer and/or tumor growth; angiogenesis, diabetes and neurological disorders | TEIJIN PHARMA LIMITED (JP) | 2010-02-23 | — | — | US | disclosed |
| EP-1780212-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE | Teijin Pharma Limited (JP) | 2007-05-02 | — | — | EP | disclosed |
| US-20060135514-A1 | Pyrazolo[1,5-a]pyrimidine derivatives | TEIJIN PHARMA LIMITED | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135514-A1 | Pyrazolo[1,5-a]pyrimidine derivatives | MAPKAPK2, MAPKAPK5, MAP4K2 | HDAC6 1671/4885MLYCD 4246/4885CA2 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.